[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-carcinoma-of-the-hypopharynx\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-carcinoma-of-the-hypopharynx":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100588919","immune-biomarker-study-for-cisplatin-ineligible-patients-receiving-chemoradiotherapy-with-docetaxel-100588919",false,"NCT06947668","Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel","DoIT_Neck","Inclusion Criteria:\n\n* Patients with squamous cell carcinomas of the oropharynx, larynx and oral cavity for whom definitive or postoperative chemoradiation is indicated\n* Patients who are cisplatin-unfit for chemotherapy, defined as:\n\n  * ECOG 2\n  * Organ dysfunction ≥ 2 according to National Cancer Institute Common Toxicity Criteria (NCI CTC) Version 4.0, such as hearing loss or tinnitus or neurological diseases\n  * Calculated creatinine clearance of ≤50ml\u002Fmin\n  * Impaired organ function or comorbidities that preclude the use of cisplatin, e.g.: left ventricular ejection fraction \\\u003C 50%, uncorrectable renal insufficiency with elevated creatinine despite creatinine clearance of 50ml\u002Fmin due to increased body weight, uncontrolled hypertension\n  * Poor nutritional status BMI \\\u003C 16kg\u002Fm²\n  * Concomitant use of nephrotoxic drugs that cannot be discontinued or converted due to other illnesses.\n  * Willingness of patients to provide blood, saliva and stool samples and consent to the preservation of all samples for study purposes\n  * Age ≥ 18 years\n  * Sufficient cognitive abilities of the patients to understand the purpose of the study and to consent to it\n\nExclusion Criteria:\n\n* Distant metastases at the time of diagnosis and simultaneous second cancers, i.e. at the time of study inclusion\n* Malignancies in the last 5 years regardless of location (except basal cell carcinoma or cervical uteri)\n* Carcinomas in which no sample collection is possible or likely without compromising the pathological assessment\n* Persistent drug or medication abuse\n* Patients who are unwilling or unable to comply with the protocol and receive treatment\n* Patients who are unsuitable for participation in the study due to a language barrier","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","Analysis of tumor tissue (which is already available in pathology) and collection of saliva\u002Fstool and blood samples, which are obtained as part of a routine collection. These will be evaluated together with the patients' clinical data to identify possible predictors for treatment feasibility, survival, tumor control and potentially increased tumor immunogenicity by docetaxel.",[24,25,26,27],"Squamous Cell Carcinoma of Oropharynx","Squamous Cell Carcinoma of the Hypopharynx","Larynx Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma","RECRUITING","2026-03-11",{"date":31,"type":32},"2026-03-12","ACTUAL",{"date":34,"type":32},"2025-05-01",{"date":36,"type":20},"2030-12-31",{"name":38,"class":39},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100518430","phase-2-de-intensification-of-postoperative-radiotherapy-in-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-100518430","NCT06030440","De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","DIREKHT2","Inclusion Criteria:\n\n1. Histologically proven squamous cell carcinoma of the oral cavity\u002Flarynx\u002Foro-or hypopharynx (except glottis cancer (pT1\u002F2pN0))\n2. Surgery of primary tumor and neck dissection performed according to predefined surgical standard\n3. Indication for postoperative radio(chemo)therapy\n4. No lymph node metastases \\> 6cm\n5. Lymph node metastases in not more than 3 lymph node level\n6. No distant metastases (cM0)\n7. Age ≥ 18 years, no upper age limit\n8. Eastern Cooperative Oncology Group (ECOG) ≤ 2\n9. Patients who understood protocol contents and are able to behave according to protocol\n10. Signed study-specific consent form prior to therapy\n11. Start of radiotherapy at least 6 weeks after last tumor-specific surgery (e.g. resection primary tumor, neck dissection, excluded are surgeries according to wound healing complications)\n\nExclusion Criteria:\n\n1. macroscopic incomplete resection R2\n2. Distant metastases (cM1)\n3. Radiologically or histologically proven early recurrence after surgery (time frame from surgery to start of radio(chemo)therapy)\n4. Lymph node metastases in \\> 3 lymph node level\n5. pregnant or lactating\u002Fnursing women\n6. fertile patients that are not willing to use highly effective methods of contraception (per institutional standards) during treatment\n7. Any condition potentially hampering compliance with the study protocol and follow-up schedule\n8. On-treatment participation on other clinical therapeutic trials\n9. Prior tumor-specific therapy any other than surgery (like prior radiotherapy in the head and neck region, prior chemo- or immunotherapy (neoadjuvant\u002Finduction))\n10. Patients who have contraindication for MRI and CT with contrast agent (both)\n11. Prior (\\> 2 months before beginning of radio(chemo)therapy) neck dissection or surgery in the head and neck area affecting lymph drainage\n12. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before diagnosis of head and neck cancer, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ without evidence of disease",{"count":49,"type":20},508,"INTERVENTIONAL",[52,53],"PHASE2","PHASE3","This randomized, prospective, multicenter phase II\u002FIII trial will study the reduction of radiation volume by eliminating radiotherapy (RT) to the elective neck using strictly defined surgical and radio-oncological standards to reduce radiotherapy-related long-term side effects without affecting locoregional control.",[56,57,25,58],"Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Oropharynx",{"date":60,"type":32},"2026-03-13",{"date":62,"type":32},"2024-01-26",{"date":64,"type":20},"2033-09",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":50,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100497046","phase-2-fluorescence-guided-surgery-in-laryngeal--and-hypopharyngeal-cancer-a-feasibility-trial-100497046","NCT05752149","Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial","The STELLAR Trial: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial","STELLAR","Inclusion Criteria:\n\n* Patients with biopsy-proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE;\n* ≥ 18 years of age;\n* Written informed consent must be obtained;\n* Sufficient knowledge of the Dutch language to understand the informed consent form;\n\nExclusion Criteria:\n\n* History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent;\n* Other synchronous biopsy proven malignancies currently active, except for adequately treated in situ carcinoma of cervix and basal, squamous cell skin carcinoma, or other head- and neck squamous cell cancer;\n* Patients pregnant or breastfeeding;\n* Patients with renal insufficiency (defined as eGFR \\\u003C 60);\n* Patients with previous kidney transplantation or a solitary functioning kidney;\n* Patients using medications that may significantly impair renal function (i.e. NSAIDs, particularly COX-2 inhibitors), that cannot be paused during the course of the study;\n* Patients with ASA classification of 4 or higher;\n* Patients with measured QTc of 500 ms or higher at screening;\n* Patients with laboratory abnormalities defined as:\n\n  * Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or;\n  * Total bilirubin above 3 times the ULN or;\n  * Platelet count below 100 x 109\u002FL or;\n  * Hemoglobin below 4 mmol\u002FL (females) or below 5 mmol\u002Fl (males).\n* Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired or weakened immune system, caused by either a preexisting disease or concomitant medications;",{"count":75,"type":20},27,[52],"This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.",[57,25],[80],"Tumour specific fluorescence imaging","NOT_YET_RECRUITING","2025-02-25",{"date":84,"type":32},"2025-02-26",{"date":86,"type":20},"2025-06-01",{"date":88,"type":20},"2027-03-01",{"name":90,"class":39},"Erasmus Medical Center",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":101,"studyType":21,"phases":4,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100545344","head-and-neck-carcinoma-clinical-research-platform-for-molecular-and-blood-based-biomarkers-treatment-and-outcome-100545344","NCT06380686","Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome","Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based","HEAT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand and willing to sign written informed consent\n* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)\n* Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care\n* Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving \"best supportive care only\": no later than six weeks after diagnosis\u002Frecurrence or metastatic disease\n\nExclusion Criteria: none",{"count":100,"type":20},120,"36 Months","Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent\u002Fmetastatic head and neck tumor patients.",[56,58,25,57],[105],"SCCHN","2024-11-11",{"date":108,"type":32},"2024-11-13",{"date":110,"type":32},"2024-11-07",{"date":112,"type":20},"2030-11",{"name":114,"class":39},"AIO-Studien-gGmbH",2]